Aspect Imaging
Aspect Imaging, a global leader in innovative, high-performance compact MR imaging solutions, designed the M-Series MRI to allow any researcher the ability to harness the power and insights of MRI as quickly and easily.
M-Series™ Compact MRI
The M-Series compact, high-performance, easy-to-use MRI systems allow preclinical researchers, without prior knowledge of MR physics, to now have cost-effective access to the gold standard method of soft tissue imaging for morphological and contrast agent applications. Advanced users will enjoy the flexibility of the customization options available.
Why you need to get an M-series preclinical MRI in your lab
Low purchase price
MRI, the gold standard in soft tissue imaging, is more accessible for pre-clinical researchers.
Compact, self-shielded permanent magnet
No special infrastructure or location for installation.
Well-designed animal handling system
Fully integrated physiological monitoring, heating, and anesthesia.
Easy to use software interface
Researchers, without prior knowledge of MRI, can obtain high-quality images.
Minimal operating costs
No electricity is required to generate the magnetic field, no cryogens or water are required for cooling, and the permanent magnet has no ongoing maintenance requirements.
Hardware and software add-ons for PET and bioluminescence
Multi-modal images that provide additional insights into animal models improving the results obtained.
Request a Quote
Our group of experts will be in touch with you to find the best solution that suits your research work.
Publications & Articles
(May 16, 2024) M-finite applications of the M-Series (MRI)
(May 16, 2024) Webinar: M-finite applications of the M-Series (MRI) In this webinar,
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle Plane Waves
(May 9, 2024) Enhanced Ultrafast Vector Flow Imaging (VFI) Using Multi-Angle Plane Waves
(April 24, 2024) Webinar: Accelerating the Delivery of New Treatments for Children with Neuroblastoma
(April 24, 2024) Webinar: Accelerating the Delivery of New Treatments for Children with